Subunits of NADH dehydrogenase
    1.
    发明授权
    Subunits of NADH dehydrogenase 失效
    NADH脱氢酶亚基

    公开(公告)号:US06399345B2

    公开(公告)日:2002-06-04

    申请号:US09151412

    申请日:1998-09-10

    IPC分类号: C12N906

    CPC分类号: C12N9/0036 A61K38/00

    摘要: The present invention provides four NADH dehydrogenase subunits (designated individually as NDS-1, NDS-2, NDS-3, and NDS-4 and collectively as NDS) and polynucleotides which identify and encode NDS. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NDS and a method for producing NDS. The invention also provides for use of NDS and agonists, antibodies, or antagonists specifically binding NDS, in the prevention and treatment of diseases associated with expression of NDS. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NDS for the treatment of diseases associated with the expression of NDS. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NDS.

    摘要翻译: 本发明提供四种NADH脱氢酶亚基(分别称为NDS-1,NDS-2,NDS-3和NDS-4,统称为NDS)和鉴定和编码NDS的多核苷酸。 本发明还提供了遗传工程改造的表达载体和包含编码NDS的核酸序列和产生NDS的方法的宿主细胞。 本发明还提供使用NDS和特异性结合NDS的激动剂,抗体或拮抗剂来预防和治疗与NDS表达相关的疾病。 另外,本发明提供反义分子用于编码NDS的多核苷酸用于治疗与NDS表达相关的疾病。 本发明还提供了利用多核苷酸或其片段或其补体以及特异性结合NDS的抗体的诊断测定法。

    Human apoptosis regulator
    2.
    发明授权
    Human apoptosis regulator 失效
    人类凋亡调节因子

    公开(公告)号:US06307021B1

    公开(公告)日:2001-10-23

    申请号:US09199892

    申请日:1998-11-24

    IPC分类号: C07K100

    CPC分类号: C07K14/47 A61K38/00

    摘要: The present invention provides a human apoptosis regulator protein (APRG) and polynucleotides which identify and encode APRG. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding APRG and a method for producing APRG. The invention also provides for agonists, antibodies, or antagonists specifically binding APRG, and their use, in the prevention and treatment of diseases associated with expression of APRG. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding APRG for the treatment of diseases associated with the expression of APRG. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding APRG.

    摘要翻译: 本发明提供了鉴定和编码APRG的人细胞凋亡调节蛋白(APRG)和多核苷酸。 本发明还提供了遗传工程改造的表达载体和宿主细胞,其包含编码APRG的核酸序列和生产APRG的方法。 本发明还提供了特异性结合APRG的激动剂,抗体或拮抗剂及其在预防和治疗与APRG表达相关的疾病中的用途。 此外,本发明提供了反义分子用于编码APRG的多核苷酸用于治疗与APRG表达相关的疾病的用途。 本发明还提供利用多核苷酸或其片段或其补体以及特异性结合APRG的抗体的诊断测定法。

    Polynucleotides encoding two novel human neuroendocrine-specific proteins
    4.
    发明授权
    Polynucleotides encoding two novel human neuroendocrine-specific proteins 失效
    编码两种新型人神经内分泌特异性蛋白的多核苷酸

    公开(公告)号:US5858708A

    公开(公告)日:1999-01-12

    申请号:US700607

    申请日:1996-08-12

    摘要: The present invention provides polynucleotides which identify and encode two novel human NSP-like proteins (NSPLP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NSPLP. The invention also provides for the use of substantially purified NSPLP, antagonists, and in pharmaceutical compositions for the treatment of diseases associated with the expression of NSPLP. Additionally, the invention provides for the use of antisense molecules to NSPLP in pharmaceutical compositions for treatment of diseases associated with the expression of NSPLP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding NSPLP or anti-NSPLP antibodies which specifically bind to NSPLP.

    摘要翻译: 本发明提供鉴定和编码两种新型人NSP样蛋白(NSPLP)的多核苷酸。 本发明提供了包含编码NSPLP的核酸序列的基因工程表达载体和宿主细胞。 本发明还提供使用基本纯化的NSPLP,拮抗剂和药物组合物来治疗与NSPLP表达相关的疾病。 此外,本发明提供了用于治疗与NSPLP表达相关的疾病的药物组合物中NSPLP的反义分子的用途。 本发明还描述了使用包含多核苷酸,其片段或其互补体的诊断组合物的诊断测定法,其与编码特异性结合NSPLP的NSPLP或抗NSPLP抗体的多核苷酸的基因组序列或转录物杂交。

    Human apoptosis regulator
    5.
    发明授权
    Human apoptosis regulator 失效
    人类凋亡调节因子

    公开(公告)号:US5847093A

    公开(公告)日:1998-12-08

    申请号:US773910

    申请日:1996-12-27

    CPC分类号: C07K14/47 A61K38/00

    摘要: The present invention provides a human apoptosis regulator protein (APRG) and polynucleotides which identify and encode APRG. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding APRG and a method for producing APRG. The invention also provides for agonists, antibodies, or antagonists specifically binding APRG, and their use, in the prevention and treatment of diseases associated with expression of APRG. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding APRG for the treatment of diseases associated with the expression of APRG. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding APRG.

    摘要翻译: 本发明提供了鉴定和编码APRG的人细胞凋亡调节蛋白(APRG)和多核苷酸。 本发明还提供了遗传工程改造的表达载体和宿主细胞,其包含编码APRG的核酸序列和生产APRG的方法。 本发明还提供了特异性结合APRG的激动剂,抗体或拮抗剂及其在预防和治疗与APRG表达相关的疾病中的用途。 此外,本发明提供了反义分子用于编码APRG的多核苷酸用于治疗与APRG表达相关的疾病的用途。 本发明还提供利用多核苷酸或其片段或其补体以及特异性结合APRG的抗体的诊断测定法。

    Subunits of NADH dehydrogenase
    6.
    发明授权

    公开(公告)号:US5814451A

    公开(公告)日:1998-09-29

    申请号:US785065

    申请日:1997-01-17

    CPC分类号: C12N9/0036 A61K38/00

    摘要: The present invention provides four NADH dehydrogenase subunits (designated individually as NDS-1, NDS-2, NDS-3, and NDS-4 and collectively as NDS) and polynucleotides which identify and encode NDS. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NDS and a method for producing NDS. The invention also provides for use of NDS and agonists, antibodies, or antagonists specifically binding NDS, in the prevention and treatment of diseases associated with expression of NDS. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NDS for the treatment of diseases associated with the expression of NDS. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NDS.

    ATP synthase subunits
    7.
    发明授权

    公开(公告)号:US6020474A

    公开(公告)日:2000-02-01

    申请号:US783974

    申请日:1997-01-15

    CPC分类号: C12N9/14 A61K38/00

    摘要: The present invention provides two ATP synthase subunits (designated individually as Asy-1 and Asy-2, and collectively as Asy) and polynucleotides which identify and encode Asy. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding Asy and a method for producing Asy. The invention also provides for use of Asy and agonists, antibodies, or antagonists specifically binding Asy, in the prevention and treatment of diseases associated with expression of Asy. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding Asy for the treatment of diseases associated with the expression of Asy. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding Asy.

    Human proteasome subunit proteins
    10.
    发明授权

    公开(公告)号:US5843715A

    公开(公告)日:1998-12-01

    申请号:US701935

    申请日:1996-08-23

    摘要: The present invention provides polynucleotides which identify and encode novel human proteasome subunit proteins. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding PSUB. The invention also provides for the use of substantially purified PSUB, antagonists, and in pharmaceutical compositions for the treatment of diseases associated with the expression of PSUB. Additionally, the invention provides for the use of antisense molecules to PSUB in pharmaceutical compositions for treatment of diseases associated with the expression of PSUB. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding PSUB or anti-PSUB antibodies which specifically bind to PSUB.